- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02779478
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
August 14, 2023 updated by: NYU Langone Health
A biomarker cohort study design is proposed to study whether specific airway microbiota alterations are associated with pulmonary Non-tuberculous mycobacteria (NTM) disease.
In a cohort of 200 subjects suspected of having pulmonary NTM disease, the investigators will evaluate the airway microbiome using an aliquot of the induced sputum and upper airway samples.
Since induced sputum may reflect different regions of the upper/lower airways, the investigators will evaluate the upper and lower airway microbiome in a subgroup (case-control group) of patients using samples obtained through upper airway sampling and bronchoscopy, respectively.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rosemary Schluger
- Email: Rosemary.Schluger@nyulangone.org
Study Contact Backup
- Name: Lisa Guiterrez
- Email: Lira.Gutierrez@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- New York University School of Medicine
-
Sub-Investigator:
- Stephanie Lau, MD
-
Sub-Investigator:
- Ashwin Basavaraj, MD
-
Contact:
- Maria Tarallo, MD
- Email: taralm01@nyumc.org
-
Contact:
- Adrienne Scott
- Email: scotta06@nyumc.org
-
Principal Investigator:
- Leopoldo Segal, MD
-
Sub-Investigator:
- Milan Amin, MD
-
Sub-Investigator:
- David Kamelhar, MD
-
Sub-Investigator:
- Doreen Addrizzo-Harris, MD
-
Sub-Investigator:
- Katrina Bantis, MD
-
Sub-Investigator:
- Benjamin Wu, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Utilizing cohorts built at NYU over the last several years, this project is uniquely positioned to investigate the microbiome signatures among subjects with NTM disease.
Description
Inclusion Criteria:
- History of pulmonary symptoms: cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, or chest discomfort
- Imaging abnormalities (within 2 years): defined as nodular or cavitary opacities on chest radiograph, or a computed tomography scan that shows bronchiectasis or bronchial wall thickening with associated multiple small nodules.
Definition of NTM case:
- Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy
Definition of NTM control:
- Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.
Exclusion Criteria for cohort study (Aim 1-2):
- Recent (<1 months prior) oral antibiotic or steroid use. (Continuous treatment with macrolides and inhaled steroids are acceptable >1 month prior)
- Recent smoking history
Exclusion Criteria for bronchoscopic study (Aims 3-4):
- Forced expiratory volume at one second (FEV1) < 70%of predicted.
- Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure.
- Diabetes mellitus
- Significant liver or renal disease
- Severe coagulopathy (INR > 1.4, Partial Thromboplastin Time (PTT) > 40 seconds and platelet count < 150x103 cells).
- Pregnancy
- Ethanol (ETOH) use of more than >6 beers or >4 mixed drinks daily
- Lack of capacity to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Positive NTM Culture
Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy
|
|
Negative NTM Culture
Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of airway microbiome in subjects with active pulmonary NTM disease and compare with controls
Time Frame: 4 Hours
|
Investigators will use sputum samples and brushed samples from areas of the upper airway from a cohort of 200 subjects with chronic cough and pulmonary infiltrates or airway abnormalities in whom NTM disease was suspected.
Cultures positive for NTM (cases) will be compared to those with culture negatives (controls).
Bacterial load by quantitative polymerase chain reaction (qPCR) will be used to characterize microbiome by high throughput sequencing looking for microbial biomarkers associated with NTM disease.
|
4 Hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Eating Assessment Tool (EAT-10) to evaluate the prevalence of laryngopharyngeal reflux and dysphagia/aspiration in subjects with active pulmonary NTM disease compared with controls
Time Frame: 1 Hour
|
1 Hour
|
Laryngoscopy to calculate the Reflux finding score (RFS, a validated quantitative measurement of impact of laryngopharyngeal reflux on the upper airway in adults
Time Frame: 4 Hours
|
4 Hours
|
Reflux Symptom Index evaluate the prevalence of laryngopharyngeal reflux and dysphagia/aspiration in subjects with active pulmonary NTM disease compared with controls
Time Frame: 1 Hour
|
1 Hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leopoldo Segal, MD, New York University Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2014
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
May 17, 2016
First Submitted That Met QC Criteria
May 18, 2016
First Posted (Estimated)
May 20, 2016
Study Record Updates
Last Update Posted (Actual)
August 15, 2023
Last Update Submitted That Met QC Criteria
August 14, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-01400
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Seoul National University Bundang HospitalUnknownSymptomatic BronchiectasisKorea, Republic of
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
-
Papworth Hospital NHS Foundation TrustGlaxoSmithKlineCompletedBronchiectasis | Idiopathic BronchiectasisUnited Kingdom
Clinical Trials on Bronchoscopy
-
Ankara Ataturk Sanatorium Training and Research...Yenimahalle Education and Research HospitalCompletedIntensive Care Unit | Tracheal StenosisTurkey
-
Tang-Du HospitalChanghai Hospital; The First Affiliated Hospital of Guangzhou Medical University and other collaboratorsTerminated
-
Jiayuan SunUnknown
-
Wake Forest University Health SciencesOhio State University; University of Mississippi Medical CenterCompletedBone Marrow TransplantationUnited States
-
Charite University, Berlin, GermanyUniversity of Luebeck; NeuroCure Clinical Research Center, Charite, Berlin; University... and other collaboratorsRecruiting
-
Centre Hospitalier Universitaire de NiceCompleted
-
University of VirginiaCompleted
-
University Medical Center GroningenUnknownAsthma | Allergic AsthmaNetherlands
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Instituto de Salud Carlos...UnknownBacterial Infection in COPDSpain